Immunoassay Detects Antibodies to American Trypanosomiasis
|
By LabMedica International staff writers Posted on 11 Jan 2011 |
|
Image: Light micrograph of a section through a cluster of Trypanosoma cruzi protozoans (purple, center) in the heart muscle of a patient suffering from Chagas disease (Photo courtesy of Sinclair Stammers / Science Photo Library).
A fully automated immunoassay can determine the presence of antibodies to Trypanosoma cruzi, the causative agent of Chagas disease, in human serum and plasma.
The quantitative two-step chemiluminescent microparticle immunoassay (CMIA) has been compared to an enzyme linked immunoassays (ELISA) for specificity and sensitivity. In the first step, sample, assay diluent, and paramagnetic microparticles co-coated with four chimeric T. cruzi recombinant antigens, are combined. A murine acridinium-labeled antihuman immunoglobulin (IgG) conjugate is added. After another wash cycle, pre-trigger and trigger solutions are added to the reaction mixture.
The ARCHITECT Chagas prototype assay (Abbott GmbH & Co.; Wiesbaden-Delkenheim, Germany) was tested on total of 10, 284 specimens to determine the specificity and sensitivity of the assay. The tests were done in Abbott's laboratory in Germany and in external sites in Guatemala and Brazil.
Of 10,284 specimens tested, 9,629 had a final interpretation of T. cruzi antibody-negative based on the testing algorithm used, whereas 655 specimens were determined to be T. cruzi antibody-positive. In comparison with the ELISA cruzi assay (bioMérieux; Marcy l'Etoile, France; www.biomerieux.com), the ARCHITECT assay demonstrated superior specificity (99.99% vs. 99.93%) and sensitivity (99.85% vs. 98.38%), along with excellent precision. This suggests that this CMIA has the potential to serve as single assay to determine the T. cruzi status of a given blood unit or diagnostic specimen on a fully automated instrument platform.
The authors of the study concluded that the utility of the fully automated ARCHITECT Chagas assay can be used in the diagnostic setting and for blood donor testing in endemic as well as nonendemic regions. The assay, once it is commercially available, might be used as a single test for routine testing in high-prevalence areas such as South and Central America, which would enable an economic testing strategy being highly advantageous for the target countries. Chagas disease or American Trypanosomiasis represents the third largest tropical disease burden worldwide, after malaria and schistosomiasis. The study was published in January 2011, in Diagnostic Microbiology and Infectious Disease.
Related Links:
bioMérieux
Abbott
The quantitative two-step chemiluminescent microparticle immunoassay (CMIA) has been compared to an enzyme linked immunoassays (ELISA) for specificity and sensitivity. In the first step, sample, assay diluent, and paramagnetic microparticles co-coated with four chimeric T. cruzi recombinant antigens, are combined. A murine acridinium-labeled antihuman immunoglobulin (IgG) conjugate is added. After another wash cycle, pre-trigger and trigger solutions are added to the reaction mixture.
The ARCHITECT Chagas prototype assay (Abbott GmbH & Co.; Wiesbaden-Delkenheim, Germany) was tested on total of 10, 284 specimens to determine the specificity and sensitivity of the assay. The tests were done in Abbott's laboratory in Germany and in external sites in Guatemala and Brazil.
Of 10,284 specimens tested, 9,629 had a final interpretation of T. cruzi antibody-negative based on the testing algorithm used, whereas 655 specimens were determined to be T. cruzi antibody-positive. In comparison with the ELISA cruzi assay (bioMérieux; Marcy l'Etoile, France; www.biomerieux.com), the ARCHITECT assay demonstrated superior specificity (99.99% vs. 99.93%) and sensitivity (99.85% vs. 98.38%), along with excellent precision. This suggests that this CMIA has the potential to serve as single assay to determine the T. cruzi status of a given blood unit or diagnostic specimen on a fully automated instrument platform.
The authors of the study concluded that the utility of the fully automated ARCHITECT Chagas assay can be used in the diagnostic setting and for blood donor testing in endemic as well as nonendemic regions. The assay, once it is commercially available, might be used as a single test for routine testing in high-prevalence areas such as South and Central America, which would enable an economic testing strategy being highly advantageous for the target countries. Chagas disease or American Trypanosomiasis represents the third largest tropical disease burden worldwide, after malaria and schistosomiasis. The study was published in January 2011, in Diagnostic Microbiology and Infectious Disease.
Related Links:
bioMérieux
Abbott
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Urine Chemistry Control
Dropper Urine Chemistry Control
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more